# De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

> **NCT05255302** · PHASE2,PHASE3 · RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 1360 (estimated)

## Conditions studied

- Metastatic NSCLC

## Interventions

- **DRUG:** Pembrolizumab before randomization
- **DRUG:** Chemotherapy
- **DRUG:** Pemetrexed
- **DRUG:** Pembrolizumab after randomization

## Key facts

- **NCT ID:** NCT05255302
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-02
- **Primary completion:** 2025-05
- **Final completion:** 2029-06-01
- **Target enrollment:** 1360 (ESTIMATED)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05255302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05255302, "De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05255302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*